OncoMatch/Clinical Trials/NCT07678684
A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
Is NCT07678684 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies HF1K16 for glioma.
Treatment: HF1K16 — The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5×10⁹/L, platelet count ≥ 90×10⁹/L, hemoglobin ≥ 9.0 g/dL (without transfusion or hematopoietic growth factor support within 14 days)
Kidney function
creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula)
Liver function
total bilirubin (TBIL) ≤ 1.5×ULN, ALT and AST ≤ 2.5×ULN; with liver metastases, ALT and AST ≤ 5×ULN and TBIL ≤ 3×ULN
Cardiac function
LVEF ≥ 50%; QTcF interval < 450 ms (males) or < 470 ms (females)
Adequate organ and bone marrow function as defined by the following criteria: ... (see full text for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07678684 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages